VIDEO Avacincaptad pegol shows positive GA reduction safety profile at 2 years

SAN FRANCISCO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Arshad Khanani, MD, MA, FASRS, discusses 2-year results of the GATHER2 trial investigating avacincaptad pegol for geographic atrophy. According to Khanani, patients treated with avacincaptad pegol every month saw a statistically significant decrease in…Read More